These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8374522)

  • 41. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Leuk Lymphoma; 1993 May; 10(1-2):49-56. PubMed ID: 8374523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
    Gandhi V; Plunkett W; Bonate PL; Du M; Nowak B; Lerner S; Keating MJ
    Clin Cancer Res; 2006 Jul; 12(13):4011-7. PubMed ID: 16818700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
    Esteva FJ; Soh LT; Holmes FA; Plunkett W; Meyers CA; Forman AD; Hortobagyi GN
    Cancer Chemother Pharmacol; 2000; 46(5):382-6. PubMed ID: 11127942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
    Keating MJ; Estey E; Plunkett W; Iacoboni S; Walters R; Kantarjian H; Andersson B; Beran M; McCredie KB; Freireich EJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):98-104. PubMed ID: 3859935
    [No Abstract]   [Full Text] [Related]  

  • 47. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
    Tanaka M; Yoshida S
    Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
    Estey EH; Plunkett W; Kantarjian H; Rios MB; Keating MJ
    Leuk Lymphoma; 1993; 10 Suppl():115-21. PubMed ID: 8481661
    [No Abstract]   [Full Text] [Related]  

  • 50. Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood.
    Esumi N; Todo S; Arakawa S; Imashuku S
    J Clin Oncol; 1986 Jul; 4(7):1089-93. PubMed ID: 3459812
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Studies on the cytotoxicity of cytosine arabinoside.
    Haanen C; Muus P; Raymakers R; Drenthe-Schonk A; Salden M; Wessels J
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):120-9. PubMed ID: 3892698
    [No Abstract]   [Full Text] [Related]  

  • 52. Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high-dose cytosine arabinoside.
    Caballero MD; González M; Cañizo MC; Orfao A; Nieto MJ; San Miguel JF
    Leukemia; 1992 Aug; 6(8):856-8. PubMed ID: 1640739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
    Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
    Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
    Koehl U; Hollatz G; Rohrbach E; Visschedyk K; Cinatl J; Kornhuber B; Kreuter J; Mutschler E; Schwabe D
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):467-77. PubMed ID: 17171362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC; Lin SF; Yao M; Chen TY; Tsao CJ; Chen TP
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian H; Thomas DA; Giles FJ; Freireich EJ; Cortes J; Lerner S; Keating MJ
    J Clin Oncol; 2001 Apr; 19(8):2165-70. PubMed ID: 11304768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Kornblau SM; Cortes-Franco J; Estey E
    Leukemia; 1993 Mar; 7(3):378-83. PubMed ID: 8445943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
    Plunkett W; Liliemark JO; Estey E; Keating MJ
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):159-66. PubMed ID: 3589690
    [No Abstract]   [Full Text] [Related]  

  • 59. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Hug V; Keating MJ; Chubb S
    Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM; Rustum YM; Preisler HD
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.